Proactive Investors - Run By Investors For Investors

FDA accepts Agile Therapeutics's new drug application for contraceptive patch Twirla

The regulator assigns November 16, 2019 as the goal date to collect fees for the new drug approval process
Agile Therapeutics' Twirla
Twirla is designed to be applied once weekly for three weeks, followed by a week without the patch

Agile Therapeutics Inc (NASDAQ:AGRX) stock shot up Wednesday after it announced that the US Food and Drug Administration has accepted for review its new drug application resubmission for Twirla, a promising investigational low-dose combined hormonal contraceptive patch.

Investors hailed the news sending shares in Agile Therapeutics up nearly 8.5% to $1.53 before the opening bell.

The Princeton, New Jersey-based women’s health-care company had originally submitted an application for FDA approval in June 2017.

The NDA resubmission was submitted on May 16, and Agile said it is intended to satisfy a complete response letter the regulator sent Agile, questioning the manufacturing process at a third-party facility and the adhesion properties of it proprietary patch technology called Skinfusion, among other issues.

READ: Agile Therapeutics resubmits new drug application for Twirla contraceptive patch to FDA

In a statement, Agile said its resubmitted application also includes the comprehensive results from a comparative wear study (Twirla vs. Xulane, produced by Mylan Pharmaceuticals Inc (NASDAQ:MYL) that was requested by the FDA to address patch adhesion questions, information on the company’s manufacturing process with partner Corium Inc, and other analyses.

The company had earlier expected the FDA to acknowledge its submission as a complete response in about 30 days.

The regulator has now acknowledged the resubmission as a “complete, class 2 response to the CRL” and has assigned November 16, 2019 as the Prescription Drug User Fee Act (PDUFA) goal date. That date actually is when the FDA could approve the patch. 

The PDUFA is a law passed by the US Congress which allows the FDA to collect fees from drug manufacturers to fund the new drug approval process.

“The acceptance of our NDA for review represents a significant milestone for Agile," Agile Therapeutics CEO Al Altomari said in a statement. “Now that the FDA has acknowledged our NDA resubmission as a complete response to the CRL, we look forward to continuing to work with the FDA during their review.”

Twirla, also known as AG200-15, is designed to be applied once weekly for three weeks, followed by a week without a patch. The company has eight patents covering Twirla. Its active ingredients are ethinyl estradiol, a synthetic estrogen, and levonorgestrel, a progestin.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

 

View full AGRX profile View Profile

Agile Therapeutics Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
A double helix and a medical person
March 06 2019
Leronlimab, according to the company, is an antiviral agent candidate with fewer side effects, lower toxicity and less frequent doses than daily HIV therapies now in use
Oncoprex
October 17 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use